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Abstract
Cystic fibrosis (CF) is a fatal, genetic disorder that critically affects the lungs and is
directly caused by mutations in the CF transmembrane conductance regulator  (CFTR)
gene,  resulting  in  defective  CFTR  function.  In  epithelial  cells,  the  CFTR  channel
conducts anions and plays a critical role in regulating the volume and composition of
airway surface liquid. This thin layer of aqueous fluid and mucus covering the airway
surface facilitates mucociliary clearance, bacterial killing, and epithelial cell homeosta‐
sis. The importance of the CFTR channel in macrophages was revealed in recent work
that demonstrated that defective CFTR function is accompanied by impaired innate
immune responses to specific infections. Notably, most CF‐associated infections are
caused by microbes that are cleared by autophagy in healthy cells. Autophagy is a
highly regulated biological process that provides energy during periods of stress and
starvation. Autophagy clears pathogens, inflammatory molecules, and dysfunctional
protein  aggregates  within  macrophages.  However,  this  process  is  impaired  in  CF
patients and CF mice, as their cells exhibit limited autophagy activity. The mechanisms
linking a malfunctioning ion channel  function to the defective autophagy remains
unclear. In this chapter, we describe and discuss the recent findings indicating the
presence of several mechanisms leading to defective autophagy in CF cells. Thus, these
novel data advance our understanding of mechanisms underlying the pathobiology of
CF and provide a new therapeutic platform for restoring CFTR function and autophagy
in patients with CF.
Keywords: cystic fibrosis (CF), autophagy, Rab GTPases (Rabs), CF‐associated bacte‐
ria, autophagy therapeutics
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1. Introduction
Cystic fibrosis (CF) is the most common life‐threatening genetic disease in North America
and Europe. The birth prevalence of CF is estimated to be one in 3500–4500, with 200–300
new cases each year in Europe. The typical form of CF is diagnosed during early childhood
and is characterized by recurrent pulmonary infections, pancreatic insufficiency, and elevated
chloride concentrations in sweat. CF is a multi‐organ disorder, however infections often occur
in the lungs accompanied with severe inflammation and tissue destruction [1]. CF is directly
caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, resulting in
defective CFTR function. Over 1400 mutations have been identified in the CFTR gene, the
most common mutation leading to CF is deletion of phenylalanine at position 508 (F508del)
and is present in over 70% of the CF alleles [2, 3]. Most of the work discussed in this chapter
refers to the F508del‐CFTR.
The previous commonly accepted hypothesis for CF pathology is the excessive secretion of
thick mucus that remains in the lungs and is accompanied by impaired mucociliary clearance.
This viscous mucus layer predisposes CF patients to chronic pulmonary infections. An
intriguing speculation arose from the specificity of organisms that tend to infect CF patients.
We hypothesized that the susceptibility of CF patients to these infectious agents is due to weak
autophagic activity since most of the organisms that tend to cause chronic infection in CF are
controlled by autophagy in healthy cells [4–6]. Autophagy is a highly regulated biological
process that provides energy during periods of stress and starvation [7] and is typically
induced upon glucose or amino acid starvation. Autophagy clears pathogens, inflammatory
molecules, and dysfunctional protein aggregates within macrophages. Autophagy proceeds
through sequential steps that begin with the formation of the phagophore or isolation mem‐
brane at a pre‐autophagosomal structure (discussed in chapter of this book) [8]. The nascent
autophagic membrane elongates to form a double‐membrane autophagosomes that captures
regions of cytoplasm, damaged mitochondria, or aggregated proteins. Upon maturation, the
autophagosome containing the isolated cargo then fuses with the lysosome to form a single
membrane compartment called the autolysosome. The autophagosomal cargo is then degrad‐
ed in this compartment by lysosomal acid hydrolases and other degradative enzymes. The
resulting degradation products including free amino acids, fatty acids, and nucleotides are
released to the cytoplasm by the action of lysosomal permeases, where they may be reutilized
for anabolic pathways [9, 10]. However, this process is impaired in CF patients and CF mice,
as their macrophages and epithelial cells exhibit limited autophagic activity. The mechanisms
linking a malfunctioning ion channel to the defective autophagy remains unclear.
Until recently, it was believed that the production of thick mucus and the impairment of
mucociliary clearance was the main underlying culprit, allowing the persistence of specific
infections in the CF lung. The idea of the existence of an innate immune deficiency disorder in
CF was not examined until lately. The discovery that the innate immune functions of macro‐
phages and neutrophils are disrupted in CF was a turning point in the CF field and in
understanding the pathobiology of CF. Several years were consumed to provide what is now
undisputable data confirming that CF should be considered an innate immune disorder.
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In this chapter, we describe and discuss the recent findings in the field, which demonstrate
that CF is a newly recognized innate immune deficiency disorder. We will discuss several
reports demonstrating that macrophage functions are disrupted in CF contributing to the
pathobiology of the disease. This chapter, encompassing recent data in CF, suggests that
targeting autophagy may be exploited as a novel strategy for treatment of CF.
2. Cystic fibrosis
The cystic fibrosis transmembrane conductance regulator (CFTR) protein is an integral
membrane glycoprotein that functions as a cAMP‐activated and phosphorylation‐regulated
Cl channel at the apical membrane of epithelial cells. CFTR is a member of the ATP‐binding
cassette transporter superfamily. It is a multi‐domain glycoprotein whose biosynthesis,
maturation, and functions involve multi‐level posttranslational modifications and complex
folding processes to reach its native, tertiary conformation. The topology of CFTR includes
two transmembrane‐spanning domains, two nucleotide‐binding domains, and a regulatory
domain, which is a unique feature among ATP‐binding cassette transporters (Figure 1) [11].
The newly synthesized CFTR emerges out of the ribosome and is targeted through the signal
recognition particle to the ER membrane translocon [12, 13]. The CFTR polypeptide chain
emerges into the ER lumen, and its glycosylated helping stabilize the protein. CFTR follows
the secretory pathway through the Golgi in order to reach the plasma membrane [14]. The
recycling of internalized CFTR channels is important for maintaining a functional pool of CFTR
at the plasma membrane.
Only 20–40% of the nascent chains achieve folded conformation, whereas the remaining
molecules are targeted for degradation by endoplasmic reticulum, lysosomes, or autophagy.
A large number of mutations impair processing of CFTR. Growing knowledge of CFTR
biosynthesis has enabled understanding of the cellular basis of CF and has brought to light
various potential targets for novel and promising therapies [15]. The most common mutation
leading to CF is deletion of phenylalanine at position 508 (F508del) and is present in over 70%
of the CF alleles [2, 3]. As mutant CFTR is targeted for degradation by the proteasome, the
formation of protein aggregates occurs, hence provoking an unfolded protein response (UPR)
[16]. Other common mutations such as the G551D exhibit defective CFTR function, however
it does not aggregate or elicit a UPR. Comparing the phenotypes and immune functions of the
F508del and G551D mutants will discern if defective bacterial clearance and uncontrolled
inflammation are due to defective channel function, UPR, or both.
Hyper‐inflammation and failure to clear infection is recognized as a leading cause of lung
tissue destruction in CF [17] that can be explained, at least in part, by incompetent autophagy
machinery in cells with a dysfunctional CFTR channel [18]. Bronchoalveolar lavages from CF
patients contain high levels of the pro‐inflammatory cytokine interleukin (IL)‐1β [1, 19–26].
IL‐1β is primarily expressed as a precursor inactive molecule that is later cleaved by caspase‐1
to yield active 17‐kDa IL‐1β [27]. The biological activities of IL‐1β include promoting inflam‐
matory responses and leukocyte infiltration. Autophagy directly regulates the level of pro‐
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IL‐1β in response to lipopolysaccharide (LPS) and infections [28, 29]. Interestingly, stimulation
of autophagy by rapamycin dramatically reduced signs of inflammation in the murine CF
lung [30, 31].
Figure 1. Autophagy process is impaired in CF cells preventing bacterial clearance.
Several reports demonstrated multiple malfunctions in adaptive and innate immune responses
in CF. Lack of functional CFTR in CD3+ lymphocytes leads to aberrant cytokine secretion and
hyper‐inflammatory adaptive immune responses [32] while producing high levels of IL‐1β [1,
19]. Naive cystic fibrosis T cells are intrinsically predisposed to differentiate toward a Th17
phenotype [33]. Therefore, CF is a multifaceted immune deficiency disease.
3. Rabs and the cytoskeleton: common modulators or innocent bystanders
for autophagy and CFTR trafficking?
Rab (Ras‐related proteins in brain) proteins are key regulators of both vesicular transport and
trafficking of proteins [34]. Several Rab GTPases have been implicated in the regulation of the
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intracellular transport and the plasma membrane delivery of CFTR. The trafficking of CFTR
from the plasma membrane to early endosomes is controlled by RAB5 [35, 36]. RAB7 regulates
the movement of CFTR away from the recycling pathway and into late endosomes and also
from late endosomes to lysosomes for degradation [37]. RAB9, however, can move CFTR away
from lysosomal degradation by mediating its transport from late endosomes back to the trans-
Golgi, from which CFTR may reenter the secretory pathway leading to plasma membrane
insertion [37].
Growing knowledge of CFTR biosynthesis has enabled understanding of the cellular basis of
CF and has brought to light various potential targets for novel and promising therapies [15].
Although some in vitro studies have shown that F508del-CFTR cell surface expression can be
increased through the manipulation of key Rab GTPases, the mechanisms involved are still
unclear. Rabs are also related to autophagy by regulating the transport and fusion of auto-
phagosomes. However, it remains unclear how each cycle of Rab activation/inactivation is
finely regulated. There is evidence indicating that RAB1, RAB5, and RAB7 participate in certain
steps of autophagosome development and maturation [38], but the specific function of some
of these Rab proteins remains poorly characterized. Conversely, RAB7, a low molecular weight
GTPase found mainly on late endosomes, has been extensively studied [38]. By interacting
with its partners (including upstream regulators and downstream effectors), RAB7 regulates
mechanisms in endosomal sorting, biogenesis of lysosome, and phagocytosis [37]. Particularly,
RAB7 governs early-to-late endosomal maturation, microtubule minus-end as well as plus-
end directed endosomal migration, and endosome-lysosome transport through different
protein–protein interaction cascades [34, 39]. In addition, RAB7 directs the maturation of
autophagosomes, by guiding the trafficking of cargos along microtubules to participate in the
fusion step with lysosomes [38]. Notably, activation of Rab7 is impaired by bacteria that tend
to infect CF patients such as Burkholderia cenocepacia, accounting at least in part for the inability
of the vacuole to merge with lysosomes [40]. Staphylococcus aureus also modulates Rabs to
establish infection [41]. Whether specific nonfunctional Rabs promote aberrant CFTR traffick-
ing and autophagy malfunction through common mechanisms in CF remains to be elucidated.
4. “Eat-me” signaling molecules: Are they trapped in CFTR aggregates?
The major molecular regulator of autophagy in response to starvation or energy depletion
include the mammalian target of rapamycin complex 1 (mTORC1). Inhibition of mTORC1 by
starvation or rapamycin results in the activation of autophagy and the start of autophagosome
formation. The capacity of autophagy to clear intracellular pathogens such as bacteria, viruses,
and parasites is collectively referred to as xenophagy [5], whereas the selective autophagic
degradation of mitochondria is denoted as mitophagy and that of protein aggregates is termed
aggrephagy. But how do autophagosomes find their targets? The modification of targets by
ubiquitination represents a signal for selection of substrates to the autophagy pathway.
Mammalian cells ubiquitinate bacteria that erroneously enter the cytosol or their containing
vacuole and target them for destruction by autophagy. Adaptors, including p62/SQSTM1 [42],
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optineurin (OPTN) [43], NBR1 (neighbor of BRCA1 gene 1) [44–46], and NDP52 (nuclear dot
protein 52 kDa) [47], mediate “eat‐me” functions by promoting autophagic sequestration of
cargo. The adaptor molecule p62 is a ubiquitously expressed cellular protein and its quantity
is critical for cell viability [48]. p62 has multiple protein‐protein interaction domains, including
the ubiquitin‐associated domain for binding of ubiquitinated cargo and a LC3 interaction
region for binding Atg8/LC3 [49]. p62 plays a role in amino acid sensing and the oxidative
Stress response, in addition to its function as an autophagy receptor for ubiquitinated cargos
[50]. Most p62 protein in the healthy cell is distributed in the cytoplasm. In response to various
stressors though, it is translocated to autophagy substrates such as protein aggregates,
damaged mitochondria, and intracellular bacteria [42]. Then, through its LC3‐binding domain,
p62 engages autophagosomes.
Autophagy is responsible for the degradation of p62. Therefore, impairment of autophagy is
usually accompanied by massive accumulation of p62 followed by the formation of aggregate
structures positive for p62 and ubiquitin [50]. This accrual is a defining characteristic of
impaired autophagy. Aggregation occurs due to both the predilection for self‐oligomerization
and the ubiquitin‐binding capabilities of p62 [51]. Notably, p62 accumulates in CF macro‐
phages and promotes the sequestration of mutant CFTR (Figure 1). These aggregates, in turn,
consume important autophagosome‐needed proteins, such as BECN1 and LC3 [30, 31]. Recent
reports demonstrate that the adapter protein NDP52 directly binds to ubiquitinated bacteria
and facilitates the assembly of an autophagic membrane that surrounds these invaders [47].
Interestingly, NDP52 can also bind ubiquitinated bacteria‐containing vacuole when p62 is
drastically reduced [30, 31]. Optineurin can mediate the removal of protein aggregates through
an ubiquitin‐independent mechanism. In addition, this protein can induce autophagy upon
overexpression or mutation [43]. NBR1 and p62 cooperate in the sequestration of misfolded
and ubiquitinated proteins in p62 bodies and are both required for their degradation by
autophagy. Recently, NBR1 was found to be necessary and sufficient for pexophagy [44–46].
Whether NBR1, optineurin, and NDP52 play important roles in CF‐associated autophagy is
still unknown.
5. Function of CFTR channel in epithelial cells
CFTR is an anion channel permeable to chloride and bicarbonate [2, 52]. Upon activation, CFTR
transports chloride following its electrochemical gradient. In the lung, CFTR is expressed at
the apical membrane of bronchial cells where it regulates chloride transport and fluid homeo‐
stasis [53]. The absence of functional CFTR in the lung results in abnormal surface hydration
and decreased airway surface fluid. Thus, mutations in the CFTR protein results in the
accumulation of thick mucus at the surface of epithelial cells, leading to impairment of
pathogen clearance and dysregulated inflammatory responses that in turn results in chronic
infection and inflammation [54]. In addition, epithelial cells expressing mutant CFTR exhibit
weak autophagy activity.
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6. Function of CFTR channel in macrophages
Macrophages are central innate immune cells that engulf invaders within a vacuole and target
them to fuse with the lysosome for degradation. Therefore, lysosomes contribute to antimi‐
crobial capacities by fusing with the pathogen‐containing, intracellular vacuole [55]. Lyso‐
somes are acidic compartments filled with various acid hydrolases, NADPH oxidases, and
oxygen radicals that degrade and break down proteins, lipids, and polysaccharides.
The lung disease seen in CF was accordingly suggested to result in part from lysosomal
dysfunction [56], yet the exact location and function of CFTR in macrophages are still debat‐
able. A report showed impaired bacterial killing due to impaired function of antibacterial
proteins at low pH in a CF pig model [57]. Another study demonstrated that acidification
requires anion transport through CFTR [58]. More recently, defective lysosomal acidification
was also invoked as the mechanism underlying CF lysosome malfunction [59]. Others failed
to confirm the involvement of CFTR in acidification [60, 61]. Both these reports are plausible.
When macrophages are infected with autophagosome‐resident organisms such as B. cenoce‐
pacia, fusion with the lysosome is impaired and acidification is reduced [30, 31, 56]. Yet, when
they are infected with phagosome‐resident organism such as Escherichia coli, fusion with the
lysosome moves swiftly and the bacterium is degraded within minutes in an acidified
compartment [30, 31]. These results suggest that the defect in lysosomal degradation is only
associated with autophagy. This explains the prevalence of several autophagy‐related organ‐
isms in CF. Actually, an acceptable approach would be to examine organisms that tend to infect
CF patient and test whether they are cleared by autophagosomes in healthy cells as was
achieved for B. cenocepacia and Pseudomonas aeruginosa. However, on the other hand, not every
organism that interacts with autophagosomes survives in CF macrophages. For example, in
our hands, Legionella pneumophila that is cleared by autophagy in wild‐type healthy macro‐
phages and survives in autophagosomes in permissive macrophages fail to establish infection
in CF macrophages (unpublished observation). How would a chloride channel alter autopha‐
gic activity is still unclear. Taken together, the role of CFTR in lysosomal function still awaits
more conclusive reports.
7. CFTR in neutrophils
Polymorphonuclear neutrophils (PMNs, neutrophils) are responsible for the earliest innate
immune response to infection and most of their antimicrobial activity against ingested
microbes is confined within phagosomes. However, exuberant neutrophil activation can
culminate in extracellular release of oxidants and granule contents that leads to local damage
to healthy tissue. Neutrophils function to kill microbes through compartmentalization by use
of membrane‐bound phagosomes, where toxic oxidants such as hydrogen peroxide (H2O2) and
hypochlorous acid (HOCl) are generated [62]. The azurophilic granule protein myeloperoxi‐
dase (MPO) catalyzes the oxidation of Cl− to form HOCl. Neutrophils predominate in the CF
patient’s lung and is a major contributor to the inflammation and destruction of the lung [63].
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Yet, despite a successful inflammatory response, neutrophils fail to eradicate invading
microbes in the CF lung [64]. CFTR dysfunction results in impaired intraphagosomal HOCl
production and neutrophil‐mediated microbial killing. Notably, the Cftr −/− lungs are deficient
in bacterial clearance, despite the sustained neutrophilic infiltration and accompanying
inflammation [65]. These events demonstrate that neutrophils with nonfunctional CFTR have
reduced capability to clear infection, yet remain capable of releasing inflammatory molecules
that destroy the lung tissue leading to decline in lung function. Some studies suggested that
CFTR channel expression in neutrophils and its dysfunction can affect neutrophil chlorination
of phagocytosed bacteria [65] and that CFTR‐dependent chloride anion transport contributes
significantly to P. aeruginosa killing by normal neutrophils [63]. Others have reported that
neutrophils from mice expressing the F508del‐CFTR or mice lacking CFTR in myeloid cells
have a pro‐inflammatory phenotype after lipopolysaccharide or bacterial [64] challenge, thus
suggesting again that CFTR expression in neutrophils might regulate their function [66].
In the CF lung, there is overproduction of the neutrophil chemotactic cytokine interleukin 8
(IL‐8). This leads to excessive infiltration of neutrophils [67]. Lung infections cause significant
morbidity and mortality in patients with CF, even in the presence of neutrophil infiltration into
infected lungs. Thus, disturbance in innate neutrophil function in CF includes excessive
recruitment [65], hyper‐production of oxidants, and increased release of degradative enzymes
[64]. Thus, it is evident that CF is indeed an innate immune disorder involving several
malfunctioning immune cells.
8. Autophagy and cystic fibrosis
Several autophagy proteins are scarcely expressed in CF cells, yet the underlying mechanism
is undefined [30, 31]. This strongly suggests the presence of an epigenic regulation that targets
autophagy mRNA in cells bearing mutant F508del‐CFTR. Considering the strong implications
of microRNAs (miRs) in autophagy [28, 29, 68–70] and given the increasing evidence showing
reduced expression of essential autophagy proteins in CF cells, we performed an in silico
approach to recognize miRs that target autophagy and are highly expressed in CF cells [71].
miRs are evolutionarily conserved class of small (∼21–24 nucleotides) noncoding RNAs that
play key roles in the transcriptional and posttranscriptional regulation of gene expression [72].
We identified the Mir17~92 cluster as being deregulated in CF [71]. This cluster generates a
single polycistronic transcript that yields six mature Mirs: Mir17, Mir18a, Mir19a, Mir20a,
Mir19b, and Mir92 [73]. miRs can regulate individual stages of these processes [72]. The
polycistronic Mir17~92 cluster was initially linked to tumorigenesis. Whether the elevated
levels in CF patients will promote cancer in aging CF population remains to be observed [73–
80]. Several specific miRs comprising the Mir17~92 cluster are overexpressed in CF human and
murine macrophages. Their expression is indirectly proportional to the expression of their
predicted autophagy‐targeted genes. Notably, reducing the inherently elevated expression of
Mir17 and Mir20a improves ATG7 and ATG16 expression both in vitro and in vivo [71]. In
addition, reducing Mir17 and Mir20a expression improves CFTR function by restoring
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autophagy expression [71]. Whether other epigenetic regulatory elements contribute to low
expression of autophagy proteins is still unclear.
In airway epithelial cells, absence of functional CFTR increases oxidative stress and
transglutaminase 2 (TGM2), a calcium‐dependent enzyme that creates intra‐ or intermolecular
covalent bonds between proteins. TGM2‐mediated cross‐linking causes sequestration of
BECN1 and its accumulation in histone deacetylase‐6 (HDAC6), p62, and ubiquitin‐containing
cytoplasmic aggresomes. BECN1 sequestration in aggresomes results in the dislodgement of
class III PtdIns3K complexes from the endoplasmic reticulum, thereby inhibiting autophagy
[30, 81]. In addition, the sequestration of BECN1 within F508‐CFTR protein aggregates
deprives the cell for an essential factor needed for autophagosome formation.
High levels of p62 promote the aggregation of mutant F508del‐CFTR sequestering several
autophagy molecules such as BECN1. This p62 buildup could be due to reduced recycling in
CF macrophages as a consequence of compromised autophagosome formation and matura‐
tion. Notably, p62 downregulation disassembles mutant CFTR and autophagy factors, thus
improving autophagy activity and allowing the maturation and trafficking of CFTR to the cell
surface in epithelial cells and bacterial clearance in macrophages [30, 31]. Similarly, genetic
manipulation or autophagy stimulatory proteostasis regulators such as cystamine restore
BECN1 availability and detangle SQSTM1/p62, which partially rescues F508del CFTR function
in airway epithelial cells and reduces lung inflammation [82].
9. Cystic fibrosis and infection
There is evidence for autophagy dysregulation in a variety of disease states, including cancer,
neurodegenerative diseases, chronic granulomatous diseases, infectious diseases, and auto‐
immune disorders [83–85]. For this reason, therapeutic modulation of autophagy is of great
interest. Autophagy has emerged as a central component of the innate and adaptive immune
responses where it plays roles in direct and indirect killing of intracellular and extracellular
pathogens, the generation of bactericidal peptides, and antigen presentation [29]. Functions of
autophagy that are compromised in CF include bacterial clearance, degradation of protein
aggregates, and the elimination of dysfunctional mitochondria. Thus, the restoration of
autophagy will have positive therapeutic effects in CF.
Patients with CF are susceptible to Nontypeable Haemophilus influenzae (NTHi), Staphylococcus
aureus (S. aureus), Burkholderia cenocepacia (B. cenocepacia), Pseudomonas aeruginosa (P. aerugino‐
sa), and nontuberculous Mycobacterium (NTM) [86–88]. The major cause of high morbidity and
mortality in CF remains the chronic respiratory infections with P. aeruginosa [89].
In healthy cells, P. aeruginosa is targeted to the autophagy pathway through yet uncharacter‐
ized mechanisms [90, 91]. Increased susceptibility of CF cells to P. aeruginosa has been
attributed to changes in airway liquid composition and enhanced bacterial binding to mucin
and epithelial cell receptors such as asialo‐GM1 [92]. In addition, disruption of lipid metabo‐
lism in CF cells increases innate inflammation in the presence of bacteria. The CFTR protein
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may also act as a receptor to P. aeruginosa and explains the high infection rate in CF patients
[93]. Although largely considered an extracellular pathogen, P. aeruginosa can invade host
airway epithelial cells where the bacteria can reside for extended periods of time. Pharmaco‐
logical improvement in autophagy in vivo effectively promoted bacterial clearance of P.
aeruginosa from the lungs.
S. aureus is one of the earliest bacteria detected in infants and children with CF. This pathogen
is the single most common CF‐associated opportunistic infection, colonizing between 50 and
68% of the population. The rise of methicillin‐resistant S. aureus (MRSA) in the past 10 years
has drawn attention to this organism [94, 95]. Unlike the other common CF‐associated
pathogens, S. aureus escapes from the phagosome upon entering the cell. In healthy cells,
cytosolic S. aureus, or those contained within damaged phagosomes, are targeted to the
autophagy pathway where they inhibit lysosomal fusion [96, 97]. The ability to escape
degradation is increased in CF cells [98].
NTM strains infect between 5 and 22% of CF patients and are a growing concern among CF
populations due to their increasing prevalence and multi‐drug resistance. Infection is often
associated with poor clinical outcomes [99]. Although autophagy contributes to clearance of
M. tuberculosis in healthy cells, it is still unclear whether NTMs can be specifically targeted for
degradation by the autophagy machinery [88].
NTHi chronically colonizes the airways of CF patients at a very young age. Recent reports
suggest that autophagy may be actively subverted by NTHi by an unknown mechanism.
On the other hand, following phagocytosis, the degradation of Aspergillus fumigatus spores
requires LC3‐associated phagocytosis for effective lysosomal degradation [100]. Whether
defective autophagy contributes to the prevalence of this infection in CF is still under investi‐
gation.
B. cenocepacia infections are not particularly common in CF patients, afflicting 3–5% of the
population, yet they are very difficult to treat due to multi‐drug resistance and are associated
with a rapid decline in lung function. In healthy macrophages, B. cenocepacia‐containing
vacuoles are targeted to the lysosome for degradation via the autophagy pathway [30, 31].
However, in CF macrophages, B. cenocepacia persists in vacuoles that do not acquire LC3 or
p62 like their counterparts in wild‐type healthy cells. These B. cenocepacia‐containing vacuoles
do not fuse with lysosomes and the bacteria evade degradation (Figure 1) [30, 31]. Similar
findings were reported in human macrophages derived from CF patients [101]. Together, these
data show that correcting autophagy activity in CF will help prevent and eradicate infectious
agents that are otherwise detrimental to the CF patients.
10. Targeting autophagy in CF improves CFTR function and bacterial
clearance
Many of the opportunistic bacteria that infect the CF lung have employed mechanisms to target
phagolysosomal maturation and/or autophagy, suggesting that these are major barriers that
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need to be overcome. Activation of autophagy through rapamycin treatment has shown
efficacy in promoting clearance of certain bacteria in vitro and in vivo [30, 102–104]. Thus, the
exploration of alternative autophagy inducing drugs is in the early stages.
Rapamycin was developed as an antifungal agent but its use was abandoned due to the potent
immunosuppressive and antiproliferative properties. Recently, it was found that rapamycin
inhibits mTOR and therefore induces autophagy [105]. Rapamycin promotes clearance of the
CF‐associated pathogens P. aeruginosa and B. cenocepacia both in vitro and in vivo in mice [30].
This could potentially be beneficial in the treatment of CF‐associated lung infection since it is
an important cause of decline in lung functions of CF patients [30]. However, rapamycin was
most effective when administrated before B. cenocepacia infection but not after. The use of
immunosuppressive drugs such as rapamycin to treat infections could negatively impact the
ability of the patients to fight other opportunistic infections. In addition, rapamycin has been
associated with significant lung toxicity in transplant recipients [106–108]. As a result,
rapamycin proved the concept that targeting autophagy is needed in CF, but represents a poor
candidate for autophagy‐inducing therapy in the treatment of CF‐associated lung infections,
and other more specific candidates are urgently needed. Thus, the field requires a safe
autophagy‐enhancing approach for CF patients.
Among the most common autophagy‐stimulating compounds were the antipsychotic drugs
bromperidol, metergoline, thioridazine, and chlorpromazine. However, the psychoactive
nature of these compounds and their potentially life‐threatening side effects limit their utility,
but nevertheless provide a strong theoretical basis for future drug development [109, 110].
Metformin is a drug that activates AMPK and therefore stimulates autophagy via TORC1‐
dependent and TORC‐1‐independent methods [111, 112]. Metformin probably has many other
mechanisms of action that cannot be explained by the induction of autophagy. Metformin and
resveratrol activate SIRT1 that in turn activates autophagy [113, 114].
Certain anticancer drugs have also been found to stimulate autophagy. For example, Perifosine
inhibits mTOR signaling through a different mechanism than classical mTOR inhibitors such
as rapamycin [115], whereas Tamoxifen, an antagonist of the estrogen receptor, is known to
induce autophagy [116]. Tamoxifen stimulates autophagy by increasing the intracellular level
of ceramide, which inhibits mTOR activation and/or stimulates expression of Atg genes.
The second generation of selective histamine H1‐receptor antagonist astemizole is a potent
inducer of autophagy at biologically achievable concentrations [117]. Astemizole exhibits
antifungal activity and antimalarial properties making it attractive option for CF patients even
though the mechanism by which it activates autophagy is still unclear [117, 118]. Safety and
drug interaction profiles of astemizole are well characterized. However, due to the availability
of superior next‐generation histamine receptor agonists, it is not commonly used in Europe or
North America.
The potential application of the TGM2 inhibitor cystamine in CF patients has recently been
reviewed. Cystamine restores normal autophagy in CFTR‐deficient cells and mouse models.
Cystamine also restores normal trafficking of the F508del‐CFTR and stabilizes the expression
of the protein at the plasma membrane of airway epithelial cells [100]. In a pilot clinical trial
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involving 10 F508del‐CFTR homozygous CF patients, the combination of cysteamine and
epigallocatechin gallate (EGCG) restored the levels of the autophagy molecules BECN1 and
p62 and improved CFTR function from nasal epithelial cells in vivo. These effects correlate with
a decrease in chloride concentrations in sweat [119]. Although the mechanism of EGCG‐
mediated autophagy is unclear, it seems like a viable option for targeting autophagy in CF.
Depletion of p62 in CF cells disintegrates the mutant CFTR aggregates and releases sequestered
molecules such as BECN1, improving overall autophagic flux in the cell. This was accompanied
by improved bacterial clearance [30, 31]. This indicates that targeting p62 in CF is a promising
approach to improve bacterial clearance and reduce inflammation in CF [30, 31]. Since the
expression of several autophagy proteins is low in CF cells, it is necessary to restore their levels
to effectively improve autophagy activity. Identifying Mir17 and Mir20a as new targets to
improve the expression of autophagy proteins and CFTR function offers a viable target in the
CF field. Further studies should explore whether other epigenetic regulatory elements
contribute to low expression of autophagy proteins in CF.
11. Concluding remarks
There is now strong evidence that immune cells, such as macrophages and neutrophils, are
intrinsically impaired in CF. We therefore, recommend that CF be added to the list of innate
immune disorders. In fact, autophagy, an intracellular degradation process that contributes to
bacterial clearance, protein degradation, and cell survival, is defective in CF. Therefore, we
propose that altered autophagy in CF contributes to chronic lung infection and inflammation.
The CF field is in desperate need for an approach to correct autophagy in CF patients. The
autophagy‐correcting agents should ameliorate the marginally positive effects of correctors
(therapies that correct the trafficking defect of F508del CFTR) and activators (compounds that
activate the F508del CFTR that reaches the cell membrane) typically used in CF. Thus, the
development of safe novel autophagy stimulating agents will improve the clinical outcome of
CF and promote the clearance of infectious agents.
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